CR8181A - Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer - Google Patents
Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancerInfo
- Publication number
- CR8181A CR8181A CR8181A CR8181A CR8181A CR 8181 A CR8181 A CR 8181A CR 8181 A CR8181 A CR 8181A CR 8181 A CR8181 A CR 8181A CR 8181 A CR8181 A CR 8181A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inhibitor
- cancer
- kinasa
- inhibition
- receiver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Describe combinaciones que comprenden un agente citotoxico y un inhibidor de cinasa EGFR y metodo para tratar o inhibir cancer en un mamifero que necesite del mismo en el cual comprende administrar al mamifero una cantidad efectiva de un agente citotoxico y un inhibidor de cinasa EGFR
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49213203P | 2003-08-01 | 2003-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR8181A true CR8181A (es) | 2006-07-14 |
Family
ID=34215843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8181A CR8181A (es) | 2003-08-01 | 2006-01-11 | Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer |
Country Status (19)
Country | Link |
---|---|
US (1) | US20050026933A1 (es) |
EP (1) | EP1648516A2 (es) |
JP (1) | JP2007501238A (es) |
KR (1) | KR20060054412A (es) |
CN (1) | CN1832757A (es) |
AR (1) | AR045179A1 (es) |
AU (1) | AU2004266572A1 (es) |
BR (1) | BRPI0413255A (es) |
CA (1) | CA2533126A1 (es) |
CO (1) | CO5640151A2 (es) |
CR (1) | CR8181A (es) |
EC (1) | ECSP066341A (es) |
IL (1) | IL173081A0 (es) |
MX (1) | MXPA06001110A (es) |
NO (1) | NO20060398L (es) |
RU (1) | RU2006106267A (es) |
TW (1) | TW200515910A (es) |
WO (1) | WO2005018677A2 (es) |
ZA (1) | ZA200600915B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1490314A1 (en) * | 2002-03-29 | 2004-12-29 | ExxonMobil Chemical Patents, Inc. a Corporation of the State of Delaware | Preparation of alkylaromatic hydrocarbons and alkylaryl sulfonates |
MXPA04009473A (es) * | 2002-03-29 | 2005-02-03 | Exxonmobil Chem Patents Inc | Oligomerizacion de olefinas. |
EP2423331B1 (en) | 2004-03-31 | 2019-05-08 | The General Hospital Corporation | Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments |
AU2005249206A1 (en) | 2004-06-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Treatment with cisplatin and an EGFR-inhibitor |
BRPI0511780A (pt) * | 2004-06-03 | 2008-01-15 | Hoffmann La Roche | tratamento com oxoliplatina e um inibidor de egrf |
DK1848414T3 (da) | 2005-02-03 | 2011-07-25 | Gen Hospital Corp | Fremgangsmåde til behandling af gefitinib-resistent cancer |
EP2594631A1 (en) | 2005-04-05 | 2013-05-22 | Cellpoint Diagnostics | Devices and method for detecting circulating tumor cells and other particles |
MX2007012662A (es) * | 2005-04-14 | 2008-04-04 | Wyeth Corp | Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib. |
NZ565654A (en) * | 2005-07-18 | 2010-10-29 | Bipar Sciences Inc | Use of iodonitrobenzamide compounds for the treatment of ovarian cancer |
ES2384267T3 (es) * | 2005-07-21 | 2012-07-03 | Nuvo Research Ag | Soluciones de clorito estabilizadas en combinación con fluoropirimidinas para el tratamiento del cáncer |
RU2451524C2 (ru) | 2005-11-04 | 2012-05-27 | Вайет | Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272 |
JP2009538317A (ja) * | 2006-05-26 | 2009-11-05 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
EP2038654A4 (en) * | 2006-06-12 | 2010-08-11 | Bipar Sciences Inc | METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS |
CN101522609A (zh) * | 2006-09-05 | 2009-09-02 | 彼帕科学公司 | 癌症的治疗 |
EP2061479A4 (en) * | 2006-09-05 | 2010-08-04 | Bipar Sciences Inc | FETTIC ACID SYNTHESIS INHIBITED BY PARP HEMMER AND TREATMENT PROCEDURES THEREWITH |
AU2007296498A1 (en) * | 2006-09-13 | 2008-03-20 | Arca Biopharma, Inc. | Methods for treating cancer |
DE102007024470A1 (de) | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
EP2217244A4 (en) * | 2007-11-12 | 2011-08-31 | Bipar Sciences Inc | TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES |
US7732491B2 (en) * | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
AU2008333786A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors |
EP2072502A1 (de) | 2007-12-20 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren |
CA2725598C (en) | 2008-06-17 | 2013-10-08 | Wyeth Llc | Antineoplastic combinations containing hki-272 and vinorelbine |
NZ590464A (en) * | 2008-08-04 | 2012-10-26 | Wyeth Llc | Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine |
RU2542963C2 (ru) * | 2008-09-05 | 2015-02-27 | Селджен Авиломикс Рисерч,Инк., | Способ определения ингибитора, ковалентно связывающего целевой полипептид |
DK3000467T3 (da) | 2009-04-06 | 2023-03-27 | Wyeth Llc | Behandling med neratinib mod brystkræft |
WO2011034907A2 (en) * | 2009-09-16 | 2011-03-24 | Avila Therapeutics, Inc. | Protein kinase conjugates and inhibitors |
EP2498751B1 (en) | 2009-11-09 | 2019-04-03 | Wyeth LLC | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
MX2012007684A (es) | 2009-12-30 | 2012-10-05 | Avila Therapeutics Inc | Modificacion covalente ligando dirigida de proteina. |
CN109045032A (zh) | 2014-01-01 | 2018-12-21 | 麦迪威森技术有限责任公司 | 氨基吡啶类化合物和使用方法 |
US9708272B2 (en) | 2014-08-29 | 2017-07-18 | Tes Pharma S.R.L. | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2020245208A1 (en) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6524832B1 (en) * | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6384051B1 (en) * | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
TW200300348A (en) * | 2001-11-27 | 2003-06-01 | American Cyanamid Co | 3-cyanoquinolines as inhibitors of egf-r and her2 kinases |
-
2004
- 2004-07-28 RU RU2006106267/15A patent/RU2006106267A/ru not_active Application Discontinuation
- 2004-07-28 CA CA002533126A patent/CA2533126A1/en not_active Abandoned
- 2004-07-28 EP EP04801904A patent/EP1648516A2/en not_active Withdrawn
- 2004-07-28 CN CNA2004800217643A patent/CN1832757A/zh active Pending
- 2004-07-28 MX MXPA06001110A patent/MXPA06001110A/es not_active Application Discontinuation
- 2004-07-28 BR BRPI0413255-6A patent/BRPI0413255A/pt not_active Application Discontinuation
- 2004-07-28 US US10/900,655 patent/US20050026933A1/en not_active Abandoned
- 2004-07-28 JP JP2006522619A patent/JP2007501238A/ja active Pending
- 2004-07-28 WO PCT/US2004/024478 patent/WO2005018677A2/en active Application Filing
- 2004-07-28 AU AU2004266572A patent/AU2004266572A1/en not_active Abandoned
- 2004-07-28 KR KR1020067002252A patent/KR20060054412A/ko not_active Application Discontinuation
- 2004-07-29 TW TW093122704A patent/TW200515910A/zh unknown
- 2004-07-30 AR ARP040102724A patent/AR045179A1/es unknown
-
2006
- 2006-01-10 IL IL173081A patent/IL173081A0/en unknown
- 2006-01-11 CR CR8181A patent/CR8181A/es unknown
- 2006-01-25 NO NO20060398A patent/NO20060398L/no not_active Application Discontinuation
- 2006-01-30 CO CO06008204A patent/CO5640151A2/es not_active Application Discontinuation
- 2006-01-31 ZA ZA200600915A patent/ZA200600915B/en unknown
- 2006-02-01 EC EC2006006341A patent/ECSP066341A/es unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0413255A (pt) | 2006-10-03 |
ZA200600915B (en) | 2007-12-27 |
JP2007501238A (ja) | 2007-01-25 |
AU2004266572A1 (en) | 2005-03-03 |
TW200515910A (en) | 2005-05-16 |
EP1648516A2 (en) | 2006-04-26 |
IL173081A0 (en) | 2006-06-11 |
MXPA06001110A (es) | 2006-04-11 |
WO2005018677A2 (en) | 2005-03-03 |
NO20060398L (no) | 2006-02-28 |
RU2006106267A (ru) | 2006-07-27 |
US20050026933A1 (en) | 2005-02-03 |
KR20060054412A (ko) | 2006-05-22 |
WO2005018677A3 (en) | 2006-05-26 |
CO5640151A2 (es) | 2006-05-31 |
ECSP066341A (es) | 2006-08-30 |
CN1832757A (zh) | 2006-09-13 |
AR045179A1 (es) | 2005-10-19 |
CA2533126A1 (en) | 2005-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR8181A (es) | Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer | |
DOP2012000290A (es) | 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer utero y cancer de ovario | |
AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
SG148202A1 (en) | Quinazolinone compounds as anticancer agents | |
PA8637301A1 (es) | Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa | |
IL174965A0 (en) | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE | |
AR028296A1 (es) | Metodos sinergisticos y composiciones para el tratamiento del cancer | |
PA8637201A1 (es) | Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa | |
CU20080027A7 (es) | Bencimidazoles sustituidos como inhibidores de cinasa | |
IL143901A0 (en) | Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia | |
ME00936B (me) | Postupci liječenja kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa | |
WO2004030625A3 (en) | Synergistic methods and compositions for treating cancer | |
CL2008002224A1 (es) | Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer. | |
MXPA05013642A (es) | Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer. | |
AR054094A1 (es) | Tratamientos de cancer | |
AR056801A1 (es) | Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina | |
MX2007011545A (es) | Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr. | |
CR9415A (es) | Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib | |
BRPI0511475A (pt) | combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer | |
WO2007016338A3 (en) | Use of chk2 kinase inhibitors for cancer treatment | |
MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
BRPI0415896A (pt) | combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia | |
CL2007002878A1 (es) | Agente farmaceutico que comprende 1) un inhibidor de her2 que tiene un esqueleto de pirrolopirimidina o de pirazolopirimidina y 2) un agente terapeutico hormonal o anticancerigeno en combinacion; y uso pra la prevencion o el tratamiento del cancer. | |
MXPA05011213A (es) | Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia. | |
BR0111785A (pt) | Composições e métodos para tratamento de candidìase |